GlaxoSmithKline appoints new executive director
GlaxoSmithKline's executive director and president of North American Pharmaceuticals, has decided to stand down from the board and is set to leave the company.
GlaxoSmithKline's executive director and president of North American Pharmaceuticals, has decided to stand down from the board and is set to leave the company.
Chris Viehbacher, who has been described by company chief executive officer Andrew Witty as making a significant contribution to the company, will be leaving on 1 December to pursue another opportunity.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.